Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q2 2022 · 10-Q
Revenue$25.60M$25.60M+7.6% vs Q2 2021 Net Income-$38.47M-$38.47MN/M vs Q2 2021 EPS Diluted-$1.31-$1.31N/M vs Q2 2021 Gross Profit$11,458,000+6.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,262,000N/M Free Cash Flowderived-$9,359,000N/M Margins · derivedGross margin44.8%−0.5 pt vs Q2 2021
Operating margin14.4%+8.6 pt vs Q2 2021
Net margin-150.3%−101.4 pt vs Q2 2021
ended Nov 28, 2021 · filed Jan 7, 2022 · 40 d after period end